Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

LOSZGENPHEN

Financiado

Cerrado

What Can We Learn from Late Onset Schizophrenia? Comprehensive Genomic and Clini...

What Can We Learn from Late Onset Schizophrenia? Comprehensive Genomic and Clinical Characterization of Late Onset versus Normal and Early Onset Cases Schizophrenia (SZ) is a debilitating disorder affecting 1% of the population and shows a strong genetic component. Onset of SZ is usually before age 40, but 1.2% have onset after 40. These individuals show marked differences from... ver más

28/02/2017

TRINITY COLLEGE DU...

75K€

Presupuesto del proyecto: 75K€

Líder del proyecto

THE PROVOST FELLOWS FOUNDATION SCHOLARS THE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2017-02-28 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

TRINITY COLLEGE DUBLIN

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2013-49108-R DECODIFICANDO LA COMPLEJIDAD BIOLOGICA DEL TRASTORNO OBSESIV... 472K€ Cerrado

GenLife Genetics across the lifespan: Unraveling age-specific determ... 227K€ Cerrado

PID2020-113609RB-C21 BEGIN: FENOMICA Y METODOS DE APRENDIZAJE AUTOMATICO COMBINAD... 175K€ Cerrado

DPI2015-69585-R TRADUCIENDO INFORMACION DE ENFERMEDADES COMPLEJAS , COMPORTA... 73K€ Cerrado

SAF2010-20840-C02-01 EXPRESION GENICA Y VARIANTES GENOMICAS ASOCIADAS CON ESQUIZO... 151K€ Cerrado

EU-GEI European Network of National Schizophrenia Networks Studying... 15M€ Cerrado

Líder del proyecto

THE PROVOST FELLOWS FOUNDATION SCHOLARS THE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 75K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Schizophrenia (SZ) is a debilitating disorder affecting 1% of the population and shows a strong genetic component. Onset of SZ is usually before age 40, but 1.2% have onset after 40. These individuals show marked differences from earlier onset, including more female cases, improved cognition, and more paranoid symptoms. The burden of late-onset SZ (LOS) is likely to grow due to the ageing population in Europe. However, little research has been conducted on LOS and the genomics of LOS have not been examined. Recent technological breakthroughs have allowed the interrogation of the genome to uncover the genetic underpinnings of SZ, and genome-wide association studies (GWAS) have been successful at finding replicated associated markers. To date, studies have not examined genetic differences between LOS and earlier onset cases. The proposed study will be the largest to examine clinical and genetic correlates of LOS vs normal onset (NOS; 18-39 yrs) and vs early onset (EOS; <18 yrs), with 400 LOS and 25,000 N/EOS. Utilising WTCCC2 GWAS data (50 LOS), the minor allele of a single nucleotide polymorphism (SNP) in the gene PREX2 was GWAS-significantly more frequent in LOS vs NOS cases and this association was replicated in an independent GWAS (79 LOS). In both GWAS, the minor allele was most frequent in LOS (10-13%), intermediate in NOS (2-4%) and lowest in EOS (1-2%), suggesting a protective effect against earlier development of SZ. In controls, the frequency of the minor allele was 4-6%, indicating it was not conferring LOS-specific risk. PREX2 is part of the RAC1 pathway containing several SZ candidate genes and GWAS support association of PREX2 with working memory and processing speed. A knockout mouse model has shown SZ-related phenotypes. Identification of genetic factors protective against developing SZ may help to develop drug targets to prevent onset. If successful, funding will help me integrate fully into TCD by providing me with the framework for a major grant.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores